Moderna, Inc. (MRNA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 301.49 |
| Open | 318.09 |
| Bid | 304.80 x 800 |
| Ask | 304.80 x 3200 |
| Day's Range | 293.60 - 318.79 |
| 52 Week Range | 102.66 - 497.49 |
| Volume | |
| Avg. Volume | 13,698,220 |
| Market Cap | 123.157B |
| Beta (5Y Monthly) | 1.49 |
| PE Ratio (TTM) | 205.58 |
| EPS (TTM) | 1.49 |
| Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 306.31 |
- Editor's PickYahoo Finance
Guess who pays for all those millions of COVID-19 vaccines
Omicron happened this week. So as the medical world shifts to a yet-to-be-determined degree, a question comes to mind: Who will pay for all this? In fact, who’s paid for all the COVID fighting to date?
- Reuters
U.S. administers 468.5 mln doses of COVID-19 vaccines- CDC
The United States had administered 468,516,782 doses of COVID-19 vaccines in the country as of Saturday morning and distributed 581,107,805 doses, the U.S. Centers for Disease Control and Prevention said. Those figures are up from the 466,348,132 vaccine doses the CDC said had gone into arms by Dec. 3 out of 580,893,145 doses delivered. The CDC tally includes two-dose vaccines from Moderna and Pfizer/BioNTech,, as well as Johnson & Johnson's one-shot vaccine.
- Motley Fool
Could Moderna and AstraZeneca's mRNA Heart Failure Drug Candidate Be a Winner?
Moderna (NASDAQ: MRNA) and AstraZeneca (NASDAQ: AZN) compete against each other in some markets with their respective COVID-19 vaccines. In this Motley Fool Live video recorded on Nov. 16, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Moderna's and AstraZeneca's mRNA candidate could be a winner.
